[Immunomodulation by in vivo monoclonal antibodies during bone marrow grafts: parameters of biological monitoring].
Fifteen patients undergoing allogeneic BMT were given monoclonal antibodies (MAb). One patient received OKT3 and 5 patients an anti-LFA1 MAb to prevent the graft rejection, 7 patients received a CD5-CD8 combination for treatment of acute GvHD and 2 patients received a CD8 MAb to overcome graft rejection. One autografted patient was administered with a CD8 MAb for an hypoplasia associated with a CD8+ lymphocytosis. Biologic monitoring associated the evaluation of serum MAb level, the analysis of target cell depletion and the detection of anti MAb antibodies. Except for OKT3, the MAb dosage had to be adjusted so that the recipients remained in antibody excess as determined by in vitro monitoring. Although the patients treated with CD5-CD8 or CD8 alone exhibited complete coating of reactive cells we did not observe a complete depletion of these populations.